The Gut-Brain Axis in IBD-Anxiety/Depression Comorbidity: A Network of Four Interconnected Inflammatory Pathways
核心洞察
Approximately one-third of IBD patients experience anxiety (搜索) and a quarter suffer from depression (搜索), forming a bidirectional vicious cycle where intestinal inflammation and emotional distress amplify each other.
Four interconnected inflammatory pathways—immune inflammation, gut microbiota-metabolite interactions, neural signaling, and HPA axis dysfunction—synergistically mediate gut-brain axis disruption in this comorbidity.
Single-target anti-inflammatory interventions show variable efficacy due to pathway compensation, individual biological differences, and poor tissue selectivity, underscoring the need for multi-target therapeutic strategies.
The comorbidity of inflammatory bowel disease (搜索) (IBD) and anxiety (搜索)/depression (搜索) represents one of the most challenging clinical intersections in gastroenterology and psychiatry. A comprehensive systematic review published in the International Journal of General Medicine now synthesizes the latest evidence on how four interconnected inflammatory pathways within the gut-brain axis (GBA) drive this bidirectional relationship, while also mapping the key research controversies and future translational directions in inflammopharmacology.
The review, which analyzed peer-reviewed literature from January 2018 through December 2024, reveals that the GBA functions as a complex bidirectional network integrating neural, immune, endocrine, and microbial signals—far more than a simple anatomical pathway. Disruption of this crosstalk is now widely regarded as the central pathophysiological basis for IBD-anxiety (搜索)/depression (搜索) comorbidity.
The Scope of the Problem
Meta-analyses indicate that approximately one-third of IBD patients experience anxiety (搜索), while a quarter suffer from depression (搜索), with this population facing a significantly higher lifetime risk of depression compared to the general public. The interplay forms a self-reinforcing vicious cycle: intestinal symptoms such as abdominal pain and diarrhea amplify emotional distress, which in turn aggravates intestinal inflammatory responses. Intestinal pain also activates spinal and vagal pathways, amplifies stress signaling, promotes neural sensitization, and directly contributes to anxiety and depression.
Four Interconnected Inflammatory Pathways
The review identifies four synergistic inflammatory pathways that mediate GBA disruption in this comorbidity.
The immune-inflammatory pathway involves chronic intestinal inflammation activating mucosal immune cells, triggering excessive release of proinflammatory cytokines such as TNF-α (搜索) and IL-6. These cytokines compromise intestinal mucosal barrier integrity and can cross the blood-brain barrier or signal via vagal afferent fibers to activate microglia within the CNS. Activated microglia then release secondary inflammatory mediators that disrupt neurotransmitter balance. Animal studies support this link, with exogenous TNF-α injection shown to induce anxiety (搜索)- and depression (搜索)-like behaviors. Targeted inhibition using anti-TNF-α monoclonal antibodies (搜索) or IL-6 receptor antagonists (搜索) has been proven to alleviate both intestinal inflammation and neuroinflammation.
The gut microbiota-metabolite pathway centers on dysbiosis—reduced levels of beneficial bacteria such as Bifidobacterium and Lactobacillus alongside overgrowth of proinflammatory strains like Escherichia coli and Enterococcus. This dysbiosis alters production of short-chain fatty acids (SCFAs) and disrupts tryptophan metabolism, shifting it toward the kynurenine pathway and producing neurotoxic metabolites such as kynurenine and quinolinic acid. Reduced SCFA levels compromise blood-brain barrier function and decrease neurotransmitter synthesis, disrupting emotional regulation.
Neural inflammatory pathways, primarily involving the vagus and sympathetic nerves, mediate bidirectional inflammatory communication. The vagus nerve transmits sensory signals from the intestine to stress response centers including the amygdala and hypothalamus. Anxiety (搜索) is associated with reduced vagal tone and altered autonomic balance, which may impair intestinal motility, secretion, and mucosal barrier function. Vagal stimulation has been shown to inhibit both intestinal and central neuroinflammation while improving emotional behaviors in animal models, while vagotomy exacerbates these phenotypes.
The HPA axis pathway involves disrupted negative feedback leading to sustained cortisol elevation. Chronic hypercortisolism impairs intestinal mucosal repair, weakens barrier function, and disrupts immune-inflammatory balance. In the brain, hypercortisolism inhibits serotonin and dopamine synthesis, causes hippocampal structural damage, and promotes microglial activation. Clinically, serum cortisol levels correlate with IBD disease activity.
Research Controversies and the Case for Multi-Target Therapy
The review highlights several unresolved controversies. Three competing causal hypotheses—IBD-first, emotion-first, and bidirectional cycle—each have supporting evidence but face common limitations including unexplored intermediate variables and lack of dynamic data across disease stages. Most researchers now lean toward the bidirectional cycle model.
Critically, the review challenges the notion of a single dominant inflammatory pathway. Evidence now supports a "network regulation" paradigm: anti-TNF-α (搜索) therapy alleviates both intestinal and central inflammatory symptoms, probiotics balance gut microbiota and reduce systemic inflammation, vagal stimulation modulates both intestinal inflammation and anxiety (搜索)-related neuroinflammation, and HPA axis modulators improve both inflammatory and emotional symptom clusters.
Single-target anti-inflammatory interventions show variable efficacy due to individual biological differences, disease progression dynamics, pathway compensation, and poor tissue selectivity. For instance, probiotic response rates vary fourfold based on microbiota ecotype, and single-target anti-inflammatory therapy efficacy declines in IBD patients with disease duration exceeding five years.
Future Translational Directions
The review outlines three core paths forward. Large-scale longitudinal cohort studies combined with Mendelian randomization will help clarify temporal and causal relationships. Single-cell and spatial transcriptomics will map cell atlases in key intestinal and brain regions. Artificial intelligence and machine learning will integrate multi-omics data to uncover inflammatory biomarker combinations.
For clinical translation, the authors advocate evaluating multi-target combination therapies—biologics paired with probiotics or prebiotics, cognitive behavioral therapy, and vagal nerve stimulation—in randomized controlled trials. Novel drug development targeting the GBA, including gut-restricted anti-TNF-α (搜索) agents and CNS-penetrating SCFA analogs, alongside natural products such as curcumin and berberine with dual anti-inflammatory and neuroprotective effects, will further enrich the pharmacologic intervention system.
The review concludes that addressing unresolved gaps—clarifying initial inflammatory triggers, standardizing gut microbiota research methods, and validating biomarker-guided personalized therapies—will usher in a new era of precision inflammopharmacology for IBD-anxiety (搜索)/depression (搜索) comorbidity.